Clinical Trials for Lymphoma
826 lymphoma trials indexed, 368 currently recruiting. Updated daily from ClinicalTrials.gov.
Understanding Lymphoma
Lymphoma is a type of cancer that begins in the lymphatic system, which is part of the body’s immune system. It occurs when lymphocytes, a kind of white blood cell, grow uncontrollably and form tumors. These abnormal cells can accumulate in lymph nodes, the spleen, bone marrow, or other organs. Doctors diagnose lymphoma through a combination of physical exams, blood tests, imaging scans like CT or PET, and most importantly, a biopsy of the affected lymph node or tissue. The biopsy confirms the presence of cancerous lymphocytes and helps identify the specific subtype of lymphoma.
Common symptoms of lymphoma include swollen lymph nodes, often painless, usually in the neck, armpits, or groin. Other signs may be unexplained weight loss, fever, night sweats, fatigue, and itching. Lymphoma can affect people of all ages but is more common in adults over 60. Some types, like Hodgkin lymphoma, tend to appear in younger adults. Risk factors include a weakened immune system, certain infections such as Epstein-Barr virus, family history, and exposure to some chemicals. However, many cases develop without any clear cause.
Medically, lymphoma is significant because it is among the most common blood cancers worldwide. In the United States, about 85,000 new cases of lymphoma are diagnosed each year. It contributes to a substantial health burden, with an estimated 20,000 deaths annually. Socially, lymphoma affects patients’ quality of life due to symptoms and the need for ongoing treatment. The complexity of lymphoma subtypes and their varied behavior makes timely diagnosis and appropriate treatment essential for better outcomes.
The Lymphoma Treatment Landscape
First-line treatment for lymphoma depends on the subtype and stage of the disease. For many patients with Hodgkin lymphoma, chemotherapy combined with radiation therapy is standard. Non-Hodgkin lymphoma treatment often starts with chemotherapy regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) sometimes combined with monoclonal antibodies like rituximab. These treatments aim to induce remission by killing cancer cells and shrinking tumors. Treatment sequencing may involve multiple cycles over several months, with adjustments based on response and side effects.
When lymphoma does not respond to initial treatment or relapses, second- and third-line options are considered. These may include targeted therapies such as immunomodulators or newer monoclonal antibodies. Drugs like bendamustine or lenalidomide are examples used in relapsed or refractory cases. Stem cell transplantation is another option for eligible patients, especially if remission is achieved after salvage therapy. Clinical decisions depend on factors like patient health, lymphoma subtype, and previous treatments.
Despite advances, there are gaps in current lymphoma treatment. Some subgroups, including those with aggressive or resistant forms, respond poorly to existing therapies. Resistance to chemotherapy and relapse remain major challenges. Side effects such as infections, fatigue, and long-term organ damage can limit treatment tolerance. Research is focused on finding therapies that improve survival while reducing toxicity. Efforts include developing drugs that target specific molecular pathways and immune-based treatments to enhance the body’s ability to fight lymphoma cells.
Why Clinical Trials Matter for Lymphoma
Clinical trials offer patients access to new treatments that are not yet widely available. Participating in a trial may provide closer monitoring by healthcare teams and the chance to contribute to medical knowledge that could help others in the future. Currently, there are 826 lymphoma clinical trials indexed on ClinicalTrials.gov, with 368 actively recruiting participants. These studies cover a range of approaches, from new drug combinations to novel immunotherapies, reflecting ongoing efforts to improve outcomes for lymphoma patients.
It is important to understand the risks involved in clinical trials. New treatments may not be effective or could cause unexpected side effects. Some trials include placebo groups or compare new therapies against standard treatments, which means patients may not receive the experimental drug. Additional clinic visits and tests are often required, which can increase the time and effort needed. Patients and caregivers should discuss these factors carefully with their healthcare providers to make informed decisions.
Clinical trials for lymphoma are sponsored by a variety of organizations, including academic institutions, pharmaceutical companies, and cooperative research groups. These sponsors design and fund studies to test new therapies or strategies. ClinicalTrials.gov serves as a central registry, providing information about ongoing and completed trials worldwide. This transparency helps patients, caregivers, and doctors find relevant studies and understand the scope of research in lymphoma treatment.
What to Look for in a Lymphoma Clinical Trial
Clinical trials for lymphoma are divided into four main phases. Phase 1 trials focus on testing the safety of a new treatment and finding the right dose. Phase 2 trials look at how well the treatment works and continue to assess safety. Phase 3 trials compare the new treatment to the current standard treatments to see which is better. Phase 4 trials happen after a treatment is approved to monitor long-term effects. For lymphoma, there are 173 trials in Phase 1 and 173 in Phase 2. There are 62 trials in Phase 3, and 76 trials have no specific phase listed.
When joining a lymphoma clinical trial, you will see specific inclusion criteria. These often include age limits, which can vary depending on the study. Some trials accept only adults, while others may include children or older adults. Prior treatments are important too; some trials require you to have tried certain therapies before joining. Biomarkers, which are specific proteins or genes related to lymphoma, are often tested to see if the treatment will be effective. The stage of lymphoma and how long you have had the disease are also common factors that determine eligibility.
Exclusion criteria help protect patients and ensure accurate results. People with other serious health conditions, or comorbidities, may be excluded to reduce risks. Trials often avoid participants who take medications that could interfere with the study drug. Safety thresholds, like limits on blood counts or organ function, are set to keep patients safe. These rules help researchers focus on a group that can safely receive the treatment and provide clear data.
Practical details are important when considering a lymphoma trial. The length of the trial can vary from a few months to several years. You may need to visit the clinic regularly for tests and treatment, sometimes weekly or monthly. Travel to the trial site can be a challenge if it is far from home. Before joining, ask the research team these four questions: How long will the trial last? What are the possible side effects? How often will I need to come to the clinic? What happens if I want to stop participating? These questions help you understand what to expect and decide if the trial fits your needs.
Primary Sources and Further Reading
For more information about lymphoma and clinical trials, it is helpful to consult trusted medical sources. These websites offer detailed guides, updates on research, and patient resources. They are reliable places to learn more about lymphoma treatments and ongoing studies.
- National Cancer Institute: Lymphoma
- MedlinePlus: Lymphoma
- ClinicalTrials.gov: Lymphoma Trials
- National Heart, Lung, and Blood Institute: Lymphoma
Latest Research and Emerging Treatments for Lymphoma (2026)
Current lymphoma research includes several Phase 3 trials testing new drugs and treatment combinations to improve patient outcomes. One study is exploring the use of glofitamab combined with polatuzumab vedotin and standard chemotherapy drugs like rituximab, cyclophosphamide, doxorubicin, and prednisone for adults with untreated large B-cell lymphoma (NCT06047080). Glofitamab is a type of antibody that helps the immune system recognize and attack lymphoma cells. Polatuzumab vedotin delivers a toxic agent directly to cancer cells, aiming to kill them while sparing healthy tissue. This combination could offer a new lymphoma treatment option that balances effectiveness with safety.
Another important trial is testing tisagenlecleucel, a CAR-T cell therapy, in adults with aggressive B-cell Non-Hodgkin Lymphoma who have not responded to other treatments (NCT03570892). CAR-T therapy uses a patient’s own immune cells, modified in the lab to better identify and destroy lymphoma cells. This approach aims to provide an option for patients with limited alternatives, potentially improving survival rates. Meanwhile, research on early stage Hodgkin lymphoma includes testing brentuximab vedotin alongside chemotherapy and radiotherapy (NCT04685616). Brentuximab vedotin is an antibody-drug conjugate that targets specific lymphoma cells, delivering chemotherapy directly to them. This trial seeks to reduce side effects by tailoring treatment based on PET scan results.
These lymphoma new treatments in 2026 reflect ongoing efforts to find therapies that are more targeted and less toxic. For patients, this could mean better control of the disease with fewer side effects and improved quality of life. As lymphoma research advances, new drugs and combinations continue to be tested, offering hope for more personalized and effective lymphoma treatment options in the near future.
Frequently asked questions about Lymphoma trials
How do I find Lymphoma clinical trials?
The authoritative source for Lymphoma clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 826 lymphoma studies are currently indexed. You can search by entering "lymphoma" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new lymphoma trials and delivers a plain-language briefing every Friday explaining what changed.
What phase are most Lymphoma trials in?
Across the 826 lymphoma trials TrialsAlert indexes, the most common phase is Phase 1. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.
How many Lymphoma clinical trials are currently recruiting?
As of the latest scan, 368 lymphoma trials have a "Recruiting" status on ClinicalTrials.gov, out of 826 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting lymphoma trial matches their tracked condition.
Stay informed about lymphoma research
Get a weekly briefing with the trials that matter most.